Immunogenicity of a recombinant hepatitis B vaccine in hemophiliacs

P. M. Mannucci, A. Gringeri, M. Morfini, R. De Biasi, M. C. Tirindelli, G. Tamponi, F. Baudo, V. Carnelli, N. Ciavarella, M. Colombo, A. Zanetti

Research output: Contribution to journalArticlepeer-review


Yeast-recombinant vaccines against hepatitis B virus (HBV) are now available, but there is no information about whether or not they are immunogenic in patients with hemophilia and other congenital bleeding disorders. Twenty micrograms of a recombinant vaccine expressing the adw serotype of the hepatitis B surface antigen (HBsAg) were given to 41 patients negative for HBV markers and again after 1 and 6 months. Ten percent of the vaccinees had anti-hepatitis B surface antibody (anti-HBs) responses, with titers of 10 mIU/ml or more, 1 month after the first dose of vaccine. The percentage of anti-HBs-positive patients increased to 54% after the second dose and to 98% after the third dose, with only one non-responder. Hence, the recombinant vaccine was immunogenic, with percentages of seroconversion and anti-HBs titers similar to those achieved with plasma-derived vaccines.

Original languageEnglish
Pages (from-to)211-214
Number of pages4
JournalAmerican Journal of Hematology
Issue number4
Publication statusPublished - 1988

ASJC Scopus subject areas

  • Hematology


Dive into the research topics of 'Immunogenicity of a recombinant hepatitis B vaccine in hemophiliacs'. Together they form a unique fingerprint.

Cite this